Multi-center Study on New Cardiovascular Remodeling and Function Parameters in Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators want to explore the relationship between different configurations of hypertension and the incidence of cardiovascular events by the guidelines reference range and EMINCA recommended reference range. Then the investigators want to enroll twenty research centers and 2200 hypertensions were planned to be collected and followed up in the 12th, 24th, 36th and 48th months after being enrolled in this study. Physical examination, ECG examination, laboratory examination, echocardiography and carotid ultrasound should be taken when baseline and follow-up. Echocardiographic measurement parameters were analyzed and the relationship between the echocardiographic measurement parameters and cardiovascular events and prognosis of hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Blood Pressure on Myocardial Work in Patients With Hypertension

NCT05062811

Hypertension; Heart Disease, Hypertensive

UNKNOWN

Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives

NCT04531124

Cardiovascular Risk Factor Hypertension Renal Disease

NOT_YET_RECRUITING

Ambulatory Blood Pressure and Prognosis

NCT00005363

Cardiovascular Diseases Heart Diseases Hypertension

COMPLETED

White Coat Hypertension and Antihypertensive Treatment Effect - SCOR in Hypertension

NCT00005316

Cardiovascular Diseases Heart Diseases Hypertension

COMPLETED

Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)

NCT03708601

Essential Hypertension

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Different configurations of hypertension are important risk factor for the morbidity and mortality of cardiovascular and cerebrovascular diseases in China. Studies have shown that left ventricular hypertrophy (LVH) and left atrial enlargement caused by hypertension are independent risk factors for cardiovascular events. The LVM and LAV derived from the normal value data of Chinese healthy adults have been reported to be different from the recommended reference values in guidelines, and the distribution characteristics of hypertension remodeling are also different. However, the characteristics and outcomes of cardiac remodeling in Chinese hypertensive population and whether this difference in configuration has an impact on the treatment, prognosis and cardiovascular events of hypertensive population are still needed to be explored.

This study was to observe the relationship between blood pressure and cardiovascular remodeling evaluated by different standards in hypertensive population, and compare the relationship between different cardiac configurations and cardiovascular events in Chinese hypertensive population.

Twenty research centers and 2200 hypertensions were planned to be collected and followed up in the 12th, 24th, 36th and 48th months after being enrolled in this study. Physical examination, ECG examination, laboratory examination, echocardiography and carotid ultrasound should be taken when baseline and follow-up.

Echocardiographic measurement parameters including M-mode and two-dimensional ultrasonic parameters; doppler ultrasound parameters; relevant parameters of two-dimensional speckle tracking, myocardial work parameters; the left ventricular remodeling parameters (LVM and RWT); cardiac morphological changes; three-dimensional ultrasound parameters were analyzed and the relationship between the echocardiographic measurement parameters and cardiovascular events and prognosis of hypertension.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypertension with left ventricular hypertrophy group

2015 ASE/EACVI guideline standard: Eccentric hypertrophy, EH: LVMI\>115g/ m2（male）or LVMI\>95g/ m2（female）and RWT≤0.42 Concentric hypertrophy, CH: LVMI\>115g/ m2（male）or LVMI\>95g/ m2（female）and RWT\>0.42

Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:

Eccentric hypertrophy, EH: LVMI\>108g/ m2（male）and RWT≤0.51or LVMI\>99g/ m2（female）and RWT≤0.49 Concentric hypertrophy, CH: LVMI\>108g/ m2（male）and RWT\>0.51 or LVMI\>99g/ m2（female）and RWT\>0.49

Left ventricular hypertrophy

Intervention Type OTHER

Hypertension with normal left ventricular geometry and left ventricular concentric remodeling

Hypertension with left ventricular non-hypertrophy group

2015 ASE/EACVI guideline standard: Normal left ventricular geometry, NG: LVMI≤115g/m2（male）or LVMI≤95g/m2（female）and RWT≤0.42 Concentric remodeling, CR: LVMI≤115g/m2（male）or LVMI≤95g/ m2（female）and RWT\>0.42

Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:

Normal left ventricular geometry, NG: LVMI≤108g/ m2（male）and RWT≤0.51 or LVMI≤99g/ m2（female）and RWT\>0.49 Concentric remodeling, CR: LVMI≤108g/ m2（male）and RWT\>0.51 or LVMI≤99g/ m2（female）and RWT\>0.49

Left ventricular non-hypertrophy

Intervention Type OTHER

Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Left ventricular hypertrophy

Hypertension with normal left ventricular geometry and left ventricular concentric remodeling

Intervention Type OTHER

Left ventricular non-hypertrophy

Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 30-75 years old;
2. No antihypertensive drugs were used and three blood pressure measurements were conducted on different days, with systolic blood pressure ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or diastolic blood pressure ≥ 90 mmHg; or have a history of hypertension and are using antihypertensive drugs, even if the blood pressure is lower than 140/90 mmHg;
3. Left ventricular ejection fraction was normal (LVEF ≥ 0.5).
4. All patients agreed to participate in the experiment and signed the informed consent form.

Exclusion Criteria

1. Secondary hypertension caused by renal parenchymal diseases, renal vascular diseases, coarctation of aorta and endocrine system diseases;
2. Severe cardiovascular and cerebrovascular diseases; heart valve disease; persistent atrial fibrillation and severe arrhythmia; previously undergone cardiovascular disease surgery;
3. Abnormal liver function; abnormal renal function and diabetes;
4. Pregnant or breastfeeding women;
5. Expected survival time due to non-cardiovascular disease\<4 years;
6. Patients with poor echocardiographic image quality.

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes